GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (STU:6Y4) » Definitions » Institutional Ownership

Vicore Pharma Holding AB (STU:6Y4) Institutional Ownership : 21.46% (As of Apr. 28, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Vicore Pharma Holding AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Vicore Pharma Holding AB's institutional ownership is 21.46%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Vicore Pharma Holding AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Vicore Pharma Holding AB's Float Percentage Of Total Shares Outstanding is 0.00%.


Vicore Pharma Holding AB Institutional Ownership Historical Data

The historical data trend for Vicore Pharma Holding AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB Institutional Ownership Chart

Vicore Pharma Holding AB Historical Data

The historical data trend for Vicore Pharma Holding AB can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 17.27 17.28 17.28 17.18 12.48 12.44 22.13 22.11 21.46 21.46

Vicore Pharma Holding AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Vicore Pharma Holding AB Business Description

Traded in Other Exchanges
Address
Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines